MedImmune Completes Aviron Acquisition

16-Jan-2002

Gaithersburg, MD, January 15, 2002 -- MedImmune, Inc. announced today that it has completed its acquisition of Aviron. MedImmune acquired over 90 percent of the Aviron shares in an Exchange offer which closed January 9, 2002. Earlier today, a MedImmune subsidiary merged into Aviron, as a result of which Aviron has become a wholly-owned subsidiary of MedImmune. In the merger, each remaining Aviron share was converted into the right to receive 1.075 MedImmune shares, the same exchange ratio as in the offer.

Aviron is a biopharmaceutical company headquartered in Mountain View, California, focused on prevention of disease through innovative vaccine technologies. The company's product portfolio includes: FluMist(TM), a live virus vaccine delivered as a nasal mist for the prevention of influenza; a live parainfluenza virus type 3 vaccine; a vaccine to prevent Epstein-Barr virus, and a cytomegalovirus vaccine.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances